Genmab A/S (FRA:GE9)
Germany · Delayed Price · Currency is EUR | Market Cap | 17.99B |
| Revenue (ttm) | 3.28B |
| Net Income (ttm) | 1.35B |
| Shares Out | n/a |
| EPS (ttm) | 21.39 |
| PE Ratio | 13.33 |
| Forward PE | 22.57 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15 |
| Average Volume | 24 |
| Open | 284.30 |
| Previous Close | 268.80 |
| Day's Range | 281.00 - 290.20 |
| 52-Week Range | 155.95 - 289.00 |
| Beta | n/a |
| RSI | 71.28 |
| Earnings Date | Feb 17, 2026 |
About Genmab
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]
Financial Performance
In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.
Financial numbers in USD Financial StatementsNews
Why Are Investors Paying Attention To Genmab Stock?
Shares of Genmab (NASDAQ: GMAB) are rising ... Full story available on Benzinga.com
Genmab A/S: Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
Supports Genmab's ambition to build an AI-enabled innovation model that advances the company's vision of bringing transformative antibody medicines to patients Genmab A/S (Nasdaq: GMAB) announced ...
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
COPENHAGEN, Denmark--(BUSINESS WIRE)-- #AI--Genmab has partnered with Anthropic to advance its research and development (R&D) processes through the adoption of agentic AI capabilities.
Genmab to Present at the 44th Annual J.P. Morgan Healthcare Conference
Media Release COPENHAGEN, Denmark; January 5, 2026 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 44 th Annual J.P. Morgan Hea...
Genmab (GMAB) Ends Acasunlimab Development, Analysts Support Move
Genmab (GMAB) Ends Acasunlimab Development, Analysts Support Move
Genmab Prunes Pipeline, Sharpens Focus On Late-Stage Cancer Assets
Genmab A/S (NASDAQ: GMAB) on Monday said it will discontinue further clinical development of acasunlimab. The decision was made as part of Genmab’s strategic focus on the most value‑creating opportun...
Genmab Prunes Pipeline, Sharpens Focus On Late-Stage Cancer Assets
Genmab A/S (NASDAQ: GMAB) on Monday said it will discontinue further clinical development of acasunlimab.
Genmab (GMAB) Shifts Focus, Discontinues Acasunlimab Development
Genmab (GMAB) Shifts Focus, Discontinues Acasunlimab Development
Genmab ends development of late-stage oncology asset acasunlimab
Genmab shifts focus to Epkinly and pipeline, discontinuing development of acasunlimab. Read more here.
Genmab (GMAB) Shifts Focus from Acasunlimab to High-Potential Programs
Genmab (GMAB) Shifts Focus from Acasunlimab to High-Potential Programs
Genmab scraps development of experimental cancer therapy
Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish drugmaker said on Monday.
Genmab To Discontinue Clinical Development Of Acasunlimab To Focus On Priority Programs
(RTTNews) - Genmab A/S (GMAB), Monday announced the decision to discontinue further clinical development of acasunlimab to focus on programs with the highest potential impact, such as EPKINLY, petosem...
Genmab (GMAB) Ends Development of Acasunlimab to Focus on Promising Projects
Genmab (GMAB) Ends Development of Acasunlimab to Focus on Promising Projects
Genmab A/S: Genmab Portfolio Prioritization Update
Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher-impact opportunities across Genmab's late-sta...
Genmab Portfolio Prioritization Update
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab's strateg...
Genmab Meets Conditions For $97/shr Merus Tender Offer
(RTTNews) - Genmab A/S (GMAB), a Danish biotechnology company's subsidiary, Genmab Holding II B.V., announced on Friday that the conditions to its tender offer to acquire all Merus N.V. (MRUS) shares ...
Genmab A/S: Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to Genmab's EBITDA ...
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “O...
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions - Slideshow
Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2025 – Genmab A/S (Nasdaq: GMAB) will hold its 2025 R&D Update and ASH Data ...
Genmab (GMAB) Highlights Promising Results from EPCORE CLL-1 Trial
Genmab (GMAB) Highlights Promising Results from EPCORE CLL-1 Trial
Genmab A/S: Genmab Announces New Data from Phase 1b/2 EPCORE CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment opti...
Genmab Announces New Data from Phase 1b/2 EPCORE CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
Genmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE CLL-1 trial (NCT04623541) evaluating the efficacy and safety of epcoritamab-bysp, a T-ce...
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the efficacy...